Just as the progress over recent decades has improved the clinical evaluation and management of BD among children and adolescents, the remaining gaps serve to inform future progress.
The first part of this series covered updates on traditional psychotropics—lithium, anticonvulsants, antipsychotics, and more. Here, Part 2 examines anti-inflammatories, natural supplements, and mitochondrial therapies.
For most patients, bipolar is a disorder of depression. It’s here that they spend the majority of their days...
There appears to be some confusion regarding the efficacy of aripiprazole in bipolar mania and depression and for preventing bipolar episodes.
"Psychiatry has been frozen in time since the 80s, and hence the absence of progress since then is no surprise." So says, S. Nassir Ghaemi, MD, MPH, in the next installment of Conversations in Critical Psychiatry with Awais Aftab, MD.
A summary of some of the latest findings in bipolar disorder research.
The good, the bad, and the efficacy of lamotrigine.
Depression predominates across the lifespan in patients with bipolar disorder. Here: A discussion about (and beyond) the four FDA-approved drugs to treat symptoms.
We have nearly a dozen atypical antipsychotics to choose from, but do all of these work in bipolar disorder and which of them should we start with? Listen to the podcast.
Bipolar disorder heightens Parkinson risk, ADHD persistence may mediate bipolar spectrum disorder risk, and rapid cycling catalysts identified—these are some of the latest findings.